Keywords: AbbVie, 2013 outlook, R&D piopeline, Regulatory milestones, Abbott
AbbVie inaugural full-year outlook for 2013 in line with expectations
Article | 31 January 2013
Newly spun-out from Abbott Labs, research-based pharma company AbbVie (NYSE: ABB) yesterday confirmed it delivered strong sales growth with its ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
